APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Transient Receptor Potential Cation Channel Subfamily V Member 1

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Outlook and Growth Opportunities 2026

Report ID 174042740419 December 2025193 pages

Choose your research edition.

Industry ResearchTransient Receptor Potential Cation Channel Subfamily V Member 1 Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Transient Receptor Potential Cation Channel Subfamily V Member 1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Transient Receptor Potential Cation Channel Subfamily V Member 1 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Transient Receptor Potential Cation Channel Subfamily V Member 1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Transient Receptor Potential Cation Channel Subfamily V Member 1 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Transient Receptor Potential Cation Channel Subfamily V Member 1 market include Amgen Inc, Vitality Biopharma Inc, Toray Industries Inc, Sylentis SAU, Pila Pharma AB, Neurim Pharmaceuticals Ltd, Medifron DBT Co Ltd, Kyowa Hakko Kirin Co Ltd and Grunenthal GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Transient Receptor Potential Cation Channel Subfamily V Member 1 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Transient Receptor Potential Cation Channel Subfamily V Member 1 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Transient Receptor Potential Cation Channel Subfamily V Member 1 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Transient Receptor Potential Cation Channel Subfamily V Member 1 market.

Transient Receptor Potential Cation Channel Subfamily V Member 1 Segment by Company

Amgen Inc

Vitality Biopharma Inc

Toray Industries Inc

Sylentis SAU

Pila Pharma AB

Neurim Pharmaceuticals Ltd

Medifron DBT Co Ltd

Kyowa Hakko Kirin Co Ltd

Grunenthal GmbH

Flex Pharma Inc

DoNatur GmbH

Daewoong Pharmaceutical Co Ltd

Centrexion Therapeutics Corp

BCN Peptides SA

Amorepacific Corp

Transient Receptor Potential Cation Channel Subfamily V Member 1 Segment by Type

DD-04107

CMX-020

CA-016

Others

Transient Receptor Potential Cation Channel Subfamily V Member 1 Segment by Application

Abdominal Pain

Muscle Spasm

Immunology

Pruritus

Ophthalmology

Others

Transient Receptor Potential Cation Channel Subfamily V Member 1 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Transient Receptor Potential Cation Channel Subfamily V Member 1 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Transient Receptor Potential Cation Channel Subfamily V Member 1 key companies, revenue, market share, and recent developments.

3. To split the Transient Receptor Potential Cation Channel Subfamily V Member 1 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Transient Receptor Potential Cation Channel Subfamily V Member 1 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Transient Receptor Potential Cation Channel Subfamily V Member 1 significant trends, drivers, influence factors in global and regions.

6. To analyze Transient Receptor Potential Cation Channel Subfamily V Member 1 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transient Receptor Potential Cation Channel Subfamily V Member 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transient Receptor Potential Cation Channel Subfamily V Member 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transient Receptor Potential Cation Channel Subfamily V Member 1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transient Receptor Potential Cation Channel Subfamily V Member 1 industry.

Chapter 3: Detailed analysis of Transient Receptor Potential Cation Channel Subfamily V Member 1 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Transient Receptor Potential Cation Channel Subfamily V Member 1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Transient Receptor Potential Cation Channel Subfamily V Member 1 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Trends Table 2. Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Drivers Table 3. Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Opportunities and Challenges Table 4. Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Restraints Table 5. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue Share by Company (2021-2026) Table 7. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Key Company Manufacturing Base & Headquarters Table 9. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company, Product Type & Application Table 10. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DD-04107 Table 15. Significant Companies of CMX-020 Table 16. Significant Companies of CA-016 Table 17. Significant Companies of Others Table 18. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type (2021-2026) Table 22. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Abdominal Pain Table 24. Significant Companies of Muscle Spasm Table 25. Significant Companies of Immunology Table 26. Significant Companies of Pruritus Table 27. Significant Companies of Ophthalmology Table 28. Significant Companies of Others Table 29. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application (2021-2026) Table 33. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application (2027-2032) Table 34. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Region (2021-2026) Table 37. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Region (2027-2032) Table 39. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Market Share by Country (2021-2026) Table 42. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Market Share by Country (2027-2032) Table 44. Amgen Inc Company Information Table 45. Amgen Inc Business Overview Table 46. Amgen Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Amgen Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 48. Amgen Inc Recent Development Table 49. Vitality Biopharma Inc Company Information Table 50. Vitality Biopharma Inc Business Overview Table 51. Vitality Biopharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Vitality Biopharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 53. Vitality Biopharma Inc Recent Development Table 54. Toray Industries Inc Company Information Table 55. Toray Industries Inc Business Overview Table 56. Toray Industries Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Toray Industries Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 58. Toray Industries Inc Recent Development Table 59. Sylentis SAU Company Information Table 60. Sylentis SAU Business Overview Table 61. Sylentis SAU Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Sylentis SAU Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 63. Sylentis SAU Recent Development Table 64. Pila Pharma AB Company Information Table 65. Pila Pharma AB Business Overview Table 66. Pila Pharma AB Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pila Pharma AB Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 68. Pila Pharma AB Recent Development Table 69. Neurim Pharmaceuticals Ltd Company Information Table 70. Neurim Pharmaceuticals Ltd Business Overview Table 71. Neurim Pharmaceuticals Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Neurim Pharmaceuticals Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 73. Neurim Pharmaceuticals Ltd Recent Development Table 74. Medifron DBT Co Ltd Company Information Table 75. Medifron DBT Co Ltd Business Overview Table 76. Medifron DBT Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Medifron DBT Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 78. Medifron DBT Co Ltd Recent Development Table 79. Kyowa Hakko Kirin Co Ltd Company Information Table 80. Kyowa Hakko Kirin Co Ltd Business Overview Table 81. Kyowa Hakko Kirin Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Kyowa Hakko Kirin Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 83. Kyowa Hakko Kirin Co Ltd Recent Development Table 84. Grunenthal GmbH Company Information Table 85. Grunenthal GmbH Business Overview Table 86. Grunenthal GmbH Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Grunenthal GmbH Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 88. Grunenthal GmbH Recent Development Table 89. Flex Pharma Inc Company Information Table 90. Flex Pharma Inc Business Overview Table 91. Flex Pharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Flex Pharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 93. Flex Pharma Inc Recent Development Table 94. DoNatur GmbH Company Information Table 95. DoNatur GmbH Business Overview Table 96. DoNatur GmbH Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. DoNatur GmbH Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 98. DoNatur GmbH Recent Development Table 99. Daewoong Pharmaceutical Co Ltd Company Information Table 100. Daewoong Pharmaceutical Co Ltd Business Overview Table 101. Daewoong Pharmaceutical Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Daewoong Pharmaceutical Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 103. Daewoong Pharmaceutical Co Ltd Recent Development Table 104. Centrexion Therapeutics Corp Company Information Table 105. Centrexion Therapeutics Corp Business Overview Table 106. Centrexion Therapeutics Corp Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Centrexion Therapeutics Corp Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 108. Centrexion Therapeutics Corp Recent Development Table 109. BCN Peptides SA Company Information Table 110. BCN Peptides SA Business Overview Table 111. BCN Peptides SA Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. BCN Peptides SA Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 113. BCN Peptides SA Recent Development Table 114. Amorepacific Corp Company Information Table 115. Amorepacific Corp Business Overview Table 116. Amorepacific Corp Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Amorepacific Corp Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio Table 118. Amorepacific Corp Recent Development Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Image Figure 2. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Size (2021-2032) & (US$ Million) Figure 4. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DD-04107 Image Figure 8. CMX-020 Image Figure 9. CA-016 Image Figure 10. Others Image Figure 11. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type (2021-2032) Figure 14. Abdominal Pain Image Figure 15. Muscle Spasm Image Figure 16. Immunology Image Figure 17. Pruritus Image Figure 18. Ophthalmology Image Figure 19. Others Image Figure 20. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application (2021-2032) Figure 23. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032) & (US$ Million) Figure 26. North America Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032) & (US$ Million) Figure 32. South America Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • DD-04107
  • CMX-020
  • CA-016
  • Others
Applications
  • Abdominal Pain
  • Muscle Spasm
  • Immunology
  • Pruritus
  • Ophthalmology
  • Others
Companies covered
  • Amgen Inc
  • Vitality Biopharma Inc
  • Toray Industries Inc
  • Sylentis SAU
  • Pila Pharma AB
  • Neurim Pharmaceuticals Ltd
  • Medifron DBT Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Grunenthal GmbH
  • Flex Pharma Inc
  • DoNatur GmbH
  • Daewoong Pharmaceutical Co Ltd
  • Centrexion Therapeutics Corp
  • BCN Peptides SA
  • Amorepacific Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Dynamics
  1. 2.1 Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Trends
  2. 2.2 Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Drivers
  3. 2.3 Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Opportunities and Challenges
  4. 2.4 Transient Receptor Potential Cation Channel Subfamily V Member 1 Industry Restraints
3 Transient Receptor Potential Cation Channel Subfamily V Member 1 Market by Company
  1. 3.1 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company Revenue Ranking in 2025
  2. 3.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue by Company (2021-2026)
  3. 3.3 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company Ranking (2024-2026)
  4. 3.4 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company Manufacturing Base and Headquarters
  5. 3.5 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company Product Type and Application
  6. 3.6 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Transient Receptor Potential Cation Channel Subfamily V Member 1 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Transient Receptor Potential Cation Channel Subfamily V Member 1 Market by Type
  1. 4.1 Transient Receptor Potential Cation Channel Subfamily V Member 1 Type Introduction
  2. 4.1.1 DD-04107
  3. 4.1.2 CMX-020
  4. 4.1.3 CA-016
  5. 4.1.4 Others
  6. 4.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Type
  7. 4.2.1 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Type (2021-2032)
  9. 4.2.3 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type (2021-2032)
5 Transient Receptor Potential Cation Channel Subfamily V Member 1 Market by Application
  1. 5.1 Transient Receptor Potential Cation Channel Subfamily V Member 1 Application Introduction
  2. 5.1.1 Abdominal Pain
  3. 5.1.2 Muscle Spasm
  4. 5.1.3 Immunology
  5. 5.1.4 Pruritus
  6. 5.1.5 Ophthalmology
  7. 5.1.6 Others
  8. 5.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Application
  9. 5.2.1 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Application (2021-2032)
  11. 5.2.3 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application (2021-2032)
6 Transient Receptor Potential Cation Channel Subfamily V Member 1 Regional Value Analysis
  1. 6.1 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032)
  7. 6.3.2 North America Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032)
  10. 6.4.2 Europe Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032)
  16. 6.6.2 South America Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Country, 2025 VS 2032
7 Transient Receptor Potential Cation Channel Subfamily V Member 1 Country-level Value Analysis
  1. 7.1 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Transient Receptor Potential Cation Channel Subfamily V Member 1 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen Inc
  2. 8.1.1 Amgen Inc Company Information
  3. 8.1.2 Amgen Inc Business Overview
  4. 8.1.3 Amgen Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  6. 8.1.5 Amgen Inc Recent Developments
  7. 8.2 Vitality Biopharma Inc
  8. 8.2.1 Vitality Biopharma Inc Company Information
  9. 8.2.2 Vitality Biopharma Inc Business Overview
  10. 8.2.3 Vitality Biopharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Vitality Biopharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  12. 8.2.5 Vitality Biopharma Inc Recent Developments
  13. 8.3 Toray Industries Inc
  14. 8.3.1 Toray Industries Inc Company Information
  15. 8.3.2 Toray Industries Inc Business Overview
  16. 8.3.3 Toray Industries Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Toray Industries Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  18. 8.3.5 Toray Industries Inc Recent Developments
  19. 8.4 Sylentis SAU
  20. 8.4.1 Sylentis SAU Company Information
  21. 8.4.2 Sylentis SAU Business Overview
  22. 8.4.3 Sylentis SAU Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sylentis SAU Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  24. 8.4.5 Sylentis SAU Recent Developments
  25. 8.5 Pila Pharma AB
  26. 8.5.1 Pila Pharma AB Company Information
  27. 8.5.2 Pila Pharma AB Business Overview
  28. 8.5.3 Pila Pharma AB Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pila Pharma AB Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  30. 8.5.5 Pila Pharma AB Recent Developments
  31. 8.6 Neurim Pharmaceuticals Ltd
  32. 8.6.1 Neurim Pharmaceuticals Ltd Company Information
  33. 8.6.2 Neurim Pharmaceuticals Ltd Business Overview
  34. 8.6.3 Neurim Pharmaceuticals Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Neurim Pharmaceuticals Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  36. 8.6.5 Neurim Pharmaceuticals Ltd Recent Developments
  37. 8.7 Medifron DBT Co Ltd
  38. 8.7.1 Medifron DBT Co Ltd Company Information
  39. 8.7.2 Medifron DBT Co Ltd Business Overview
  40. 8.7.3 Medifron DBT Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Medifron DBT Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  42. 8.7.5 Medifron DBT Co Ltd Recent Developments
  43. 8.8 Kyowa Hakko Kirin Co Ltd
  44. 8.8.1 Kyowa Hakko Kirin Co Ltd Company Information
  45. 8.8.2 Kyowa Hakko Kirin Co Ltd Business Overview
  46. 8.8.3 Kyowa Hakko Kirin Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kyowa Hakko Kirin Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  48. 8.8.5 Kyowa Hakko Kirin Co Ltd Recent Developments
  49. 8.9 Grunenthal GmbH
  50. 8.9.1 Grunenthal GmbH Company Information
  51. 8.9.2 Grunenthal GmbH Business Overview
  52. 8.9.3 Grunenthal GmbH Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Grunenthal GmbH Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  54. 8.9.5 Grunenthal GmbH Recent Developments
  55. 8.10 Flex Pharma Inc
  56. 8.10.1 Flex Pharma Inc Company Information
  57. 8.10.2 Flex Pharma Inc Business Overview
  58. 8.10.3 Flex Pharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Flex Pharma Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  60. 8.10.5 Flex Pharma Inc Recent Developments
  61. 8.11 DoNatur GmbH
  62. 8.11.1 DoNatur GmbH Company Information
  63. 8.11.2 DoNatur GmbH Business Overview
  64. 8.11.3 DoNatur GmbH Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  65. 8.11.4 DoNatur GmbH Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  66. 8.11.5 DoNatur GmbH Recent Developments
  67. 8.12 Daewoong Pharmaceutical Co Ltd
  68. 8.12.1 Daewoong Pharmaceutical Co Ltd Company Information
  69. 8.12.2 Daewoong Pharmaceutical Co Ltd Business Overview
  70. 8.12.3 Daewoong Pharmaceutical Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Daewoong Pharmaceutical Co Ltd Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  72. 8.12.5 Daewoong Pharmaceutical Co Ltd Recent Developments
  73. 8.13 Centrexion Therapeutics Corp
  74. 8.13.1 Centrexion Therapeutics Corp Company Information
  75. 8.13.2 Centrexion Therapeutics Corp Business Overview
  76. 8.13.3 Centrexion Therapeutics Corp Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Centrexion Therapeutics Corp Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  78. 8.13.5 Centrexion Therapeutics Corp Recent Developments
  79. 8.14 BCN Peptides SA
  80. 8.14.1 BCN Peptides SA Company Information
  81. 8.14.2 BCN Peptides SA Business Overview
  82. 8.14.3 BCN Peptides SA Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  83. 8.14.4 BCN Peptides SA Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  84. 8.14.5 BCN Peptides SA Recent Developments
  85. 8.15 Amorepacific Corp
  86. 8.15.1 Amorepacific Corp Company Information
  87. 8.15.2 Amorepacific Corp Business Overview
  88. 8.15.3 Amorepacific Corp Transient Receptor Potential Cation Channel Subfamily V Member 1 Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Amorepacific Corp Transient Receptor Potential Cation Channel Subfamily V Member 1 Product Portfolio
  90. 8.15.5 Amorepacific Corp Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst